



Roberta Ferraldeschi

Contact

Roberta Ferraldeschi

Publications (7)

Lorente D, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, Miranda S, Riisnaes R, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, de Bono J. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. *Clin Genitourin Cancer* 2016; 14:485-493.

Ferraldeschi R, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, Altavilla A, Mateo J, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, de Bono J. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. *Eur Urol* 2014

Carreira S, Demichelis F, S de Bono J, Tunariu N, Flohr P, Rodrigues D, Omlin A, Pezaro C, Frenel J, Lorente D, Prandi D, Miranda S, Ferraldeschi R, Grist E, Goodall J, Romanel A, Attard G. Tumor clone dynamics in lethal prostate cancer. *Sci Transl Med* 2014; 6:254ra125.

Lorente D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Bianchini D, de Bono J. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. *Eur J Cancer* 2014; 50:1042-3.

Pezaro C, de Bono J, Parker C, Dearnaley D, Bianchini D, Ferraldeschi R, Lorente D, Altavilla A, Omlin A, Attard G. Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. *Eur Urol* 2013

Pezaro C, de Bono J, Tunariu N, Crespo M, Altavilla A, Riisnaes R, Mukherji D, Bianchini D, Ferraldeschi R, Nava Rodrigues D, Lorente D, Omlin A, Attard G. Visceral Disease in Castration-resistant Prostate Cancer. *Eur Urol* 2013; 65:270-3.

Omlin A, Attard G, Parker C, Thompson E, Maier G, Ferraldeschi R, Olmos D, Bianchini D, Sandhu S, Mulick Cassidy A, Mukherji D, Pezaro C, de Bono J. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. *Eur Urol* 2013; 64:300-6.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch